

TERMINAL SECRETIONS

Terminal secretions, previously referred to as the “death rattle,” are noises produced by turbulent movement of saliva in the upper airways. They occur when the larynx relaxes during the inspiratory and expiratory phases of respiration in patients who are actively dying. Patients usually are unresponsive and unable to clear secretions through swallowing or coughing. Most patients die within 48 hours of developing terminal secretions.¹

Nursing Assessment:

- Clinical assessment: Complete a focused history and physical exam, including history of symptoms (onset, pattern, precipitating and relieving events, and response to medications). Review laboratory/diagnostic test results.¹
 - ▶ Type 1 or “real” death rattle occurs when a patient’s level of consciousness has decreased.¹
 - ▶ Type 2 or “pseudo” death rattle is caused by bronchial secretions typically formed due to pulmonary pathology such as infection, aspiration, or edema.¹
 - ▶ A combination of types 1 and 2 may exist.
- The Victoria Respiratory Congestion Scale is used to quantify terminal secretions with a 0–3 scale, depending on the distance at which noisy congestion is audible.¹

Nonpharmacological Management:

- Reposition the patient to his or her side or in a semi-prone position to facilitate postural drainage if needed.²
- Reduce fluid intake and reevaluate whether the patient should be receiving intravenous (IV) fluids, tube feedings, or other IV medications.¹

Pharmacological Management*:

- Optimize treatment for any underlying etiologies.
- Anticholinergic agents are typically used to decrease secretions. Efficacy is questionable. Type 1 secretions are typically amendable.¹ Treatment will also depend on care setting.
 - ▶ Consider atropine 1% ophthalmic drops, one or two drops sublingually every one to two hours if allowed in presence of contact isolation policies and procedures; scopolamine one to three patches transdermally every three days; glycopyrrolate 0.2–0.4 mg IV or subcutaneously every four to eight hours as needed; hyoscyamine 0.125 mg via orally disintegrating tablets every three to four hours as needed.³
 - ▶ Monitor for dry mouth, urinary retention, delirium, restlessness, and constipation.^{1,2}

Additional Interventions:

- An interprofessional team with multiple perspectives can provide successful interventions for patients with terminal secretions.
- Consider referral to palliative care for advanced symptom management.

Patient and Family Education:

- Provide education on underlying etiology of secretions, treatment options, medications, and anticipated effects.
- Discuss with family that although the secretions may be distressing, the patient is not uncomfortable. Explain that terminal secretions are a normal part of the dying process for many people.¹
- Provide information to the family about nonverbal and behavioral indicators that affirm the absence of discomfort.¹
- Set realistic expectations for symptom trajectory, with reassuring education on management strategies.
- Instruct on appropriate nonpharmacological strategies and safety.

***DISCLAIMER:** Medication dosing for symptom management is only a recommendation for nursing to discuss with prescribers and for prescriber consideration after careful history, physical exam, and review of laboratory/diagnostic studies. Dosing should be adjusted based on each patient's clinical case, presentation, and prescriber's clinical judgment.

There are no drugs approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of patients with COVID-19. At present, clinical management includes infection prevention, control measures, and supportive care, including supplementary oxygen and mechanical ventilatory support when indicated. The Centers for Disease Control and Prevention also hypothesizes that angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and steroids may increase the severity of COVID-19. However, currently, there are no data to suggest a link between those medications and worse COVID-19 outcomes.⁴

For additional information, please access HPNA's COVID-19 Resource page at www.advancingexpertcare.org.

REFERENCES

1. Donesky D. Dyspnea, cough, and terminal secretions. In: Ferrell B, Paice J, eds. *Oxford Textbook of Palliative Nursing*. 5th ed. New York, NY: Oxford University Press; 2019.
2. Bickel K, Arnold R. Death rattle and oral secretions. In: *Fast Facts and Concepts*. Palliative Care Network of Wisconsin. <https://www.mypcnw.org/fast-fact/death-rattle-and-oral-secretions/>. Accessed April 3, 2020.
3. Quill T, Vyjeyanthi P, Denney-Koelsch E, White P, Zhukovsky D. Dyspnea. In: *Primer of Palliative Care*. Chicago, IL: American Academy of Hospice and Palliative Medicine; 2019; 72-80.
4. Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html#Medications>. Accessed March 30, 2020.